Dr. Reddy's Laboratories Ltd.

437 articles with Dr. Reddy's Laboratories Ltd.

• Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases

  3/20/2023

  Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced a worldwide agreement with Dr. Reddy’s Laboratories Limited.

• Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

  1/27/2023

  Dr. Reddy’s Laboratories Ltd. today announced the launch of Dr. Reddy’s Difluprednate Ophthalmic Emulsion 0.05%, a therapeutic generic equivalent to Durezol® (Difluprednate Ophthalmic Emulsion 0.05%) in the U.S. market, following the approval by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe

  1/20/2023

  Dr. Reddy’s Laboratories Ltd. announced that it has successfully completed the full set of clinical studies of its proposed rituximab biosimilar candidate, DRL_RI, for filing in highly regulated markets such as the United States, Europe and other regions.

• Theranica Enters Into Agreement With Dr. Reddy's for Commercializing Nerivio® in India

  1/10/2023

  Theranica announced a strategic license and supply agreement with Dr. Reddy's Laboratories Ltd., a global pharmaceutical company, for the exclusive marketing and distribution of FDA-approved Nerivio® in India, subject to completion of the regulatory approval process in India.

• Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29Phase 3, registrational studies remain on track for first half of 2023 topline data readout

  12/20/2022

  Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”) today announced positive PK comparability data of DFD-29 and key updates on the progress of its pivotal, Phase 3 clinical study of DFD-29 for the treatment of papulopustular rosacea in collaboration with Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”).

• Dr. Reddy’s Successfully Completes Phase 1 Study of DRL_TC, a Proposed Biosimilar of Tocilizumab

  12/19/2022

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”), a global pharmaceutical company, announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase 1 study.

• World Economic Forum Recognises Dr. Reddy’s Hyderabad Factory as Part of its Global Lighthouse Network

  10/11/2022

  Dr. Reddy’s largest manufacturing facility in Bachupally, Hyderabad, joins Global Lighthouse Network of the World Economic Forum Journey started four years ago with digitisation of infrastructure and processes.

• Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market

  7/27/2022

  Dr. Reddy’s Laboratories Ltd. announced the launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade® Injection, in the U.S. market approved by the U.S. Food and Drug Administration.

• Dr. Reddy’s Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

  7/22/2022

  Dr. Reddy’s Laboratories Ltd. announced the first-to-market launch of over-the-counter Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP, the store-brand equivalent of Allegra-D® 24 HR in the U.S. market, as approved by the U.S. Food and Drug Administration.

• Eton Pharmaceuticals Announces Sale of Hospital Products

  6/24/2022

  Eton sold its rights in Biorphen®, Rezipres®, and Cysteine Hydrochloride products for total payments of up to $50 million.

• Dr. Reddy's Laboratories announces the launch of the generic version of Nexavar (sorafenib) Tablets, USP, 200 mg in the U.S. market

  6/14/2022

  Dr. Reddy’s Laboratories Ltd. announced the launch of Dr. Reddy’s Sorafenib Tablets, USP, 200 mg, a therapeutic generic equivalent of Nexavar® Tablets in the U.S. market following the approval by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Methylprednisolone Sodium Succinate for Injection, USP in the U.S. Market

  4/5/2022

  Dr. Reddy’s Laboratories Ltd. announced the launch of Methylprednisolone Sodium Succinate for Injection, USP, the generic equivalent of SOLU-MEDROL® in the U.S. Market approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT® (vasopressin injection, USP) Vials in the U.S. Market

  2/9/2022

  Dr. Reddy’s Laboratories Ltd. announced the launch of its authorized generic version of Par Pharmaceutical’s VASOSTRICT® Vials in the U.S. Market approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Venlafaxine ER Tablets in the U.S. Market

  12/10/2021

  Dr. Reddy’s Laboratories Ltd. announced the launch of Venlafaxine ER Tablets which is therapeutically equivalent to Venlafaxine Extended-Release Tablets, 150 mg and 225 mg, of Osmotica Pharmaceutical US LLC approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Valsartan Tablets, USP in the U.S. Market

  12/9/2021

  Dr. Reddy’s Laboratories Ltd. announced the launch of Valsartan Tablets, USP, a therapeutic equivalent generic version of Diovan® Tablets approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Ephedrine Sulfate Injection USP, 50 mg/mL, Single-Dose Vial in the U.S. Market

  10/29/2021

  Dr. Reddy’s Laboratories Ltd. today announced the launch of Ephedrine Sulfate Injection USP, 50 mg/mL, a therapeutic equivalent generic version of Akovaz® (ephedrine sulfate injection) Injection, 50 mg/mL approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories Announces Approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)

  10/19/2021

  Dr. Reddy’s Laboratories Ltd. announced the final approval of its Abbreviated New Drug Application for Lenalidomide Capsules, in 2.5 mg and 20 mg strengths, and tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths, a therapeutic equivalent generic version of REVLIMID® Capsules, from the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market

  10/15/2021

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Carmustine for Injection, USP, a therapeutic equivalent generic version of BiCNU® (carmustine for injection) approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy’s Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)

  9/4/2021

  Dr. Reddy’s Laboratories Ltd., announced that it has entered into a definitive agreement with Citius Pharmaceuticals, Inc. pursuant to which it sold all of its rights to E7777 and certain related assets.

• Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian Market

  9/2/2021

  Dr. Reddy’s Laboratories Ltd. announced that Reddy-Lenalidomide, a generic equivalent to Revlimid® capsules, is approved by Health Canada and has been launched in the Canadian market.